ATE430759T1 - Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen - Google Patents

Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen

Info

Publication number
ATE430759T1
ATE430759T1 AT02712923T AT02712923T ATE430759T1 AT E430759 T1 ATE430759 T1 AT E430759T1 AT 02712923 T AT02712923 T AT 02712923T AT 02712923 T AT02712923 T AT 02712923T AT E430759 T1 ATE430759 T1 AT E430759T1
Authority
AT
Austria
Prior art keywords
liposomes
active ingredients
sterol derivatives
loading
sensitive
Prior art date
Application number
AT02712923T
Other languages
German (de)
English (en)
Inventor
Steffen Panzner
Gerold Endert
Stefan Fankhaenel
Anja Behrens
Original Assignee
Novosom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novosom Ag filed Critical Novosom Ag
Application granted granted Critical
Publication of ATE430759T1 publication Critical patent/ATE430759T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02712923T 2001-02-21 2002-02-21 Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen ATE430759T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10109898A DE10109898A1 (de) 2001-02-21 2001-02-21 Lipide mit veränderlicher Ladung
PCT/EP2002/001879 WO2002066490A2 (de) 2001-02-21 2002-02-21 Kationische sterolderivate, ph-sensitive liposomen umfassend diese und verfahren zur wirkstoffbeladung von liposomen

Publications (1)

Publication Number Publication Date
ATE430759T1 true ATE430759T1 (de) 2009-05-15

Family

ID=7675951

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02712923T ATE430759T1 (de) 2001-02-21 2002-02-21 Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen
AT02729931T ATE364620T1 (de) 2001-02-21 2002-02-21 Amphotere sterole und deren verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02729931T ATE364620T1 (de) 2001-02-21 2002-02-21 Amphotere sterole und deren verwendung

Country Status (10)

Country Link
US (3) US7312206B2 (https=)
EP (3) EP1363933B1 (https=)
JP (2) JP2004521917A (https=)
CN (1) CN1231493C (https=)
AT (2) ATE430759T1 (https=)
AU (2) AU2002244726A1 (https=)
BR (1) BR0207776A (https=)
CA (1) CA2438910C (https=)
DE (3) DE10109898A1 (https=)
WO (2) WO2002066490A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207177A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
DE10207178A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
AU2004238076A1 (en) * 2003-05-09 2004-11-25 Novosom Ag Injectable liposomal depots for delivering active ingredients
CN1849112B (zh) * 2003-09-09 2012-06-13 吉里德科学公司 治疗性脂质体
EP1547580A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Loading of a camptothecin drug into colloidal nanoparticles
WO2005063212A1 (en) * 2003-12-31 2005-07-14 Amorepacific Corporation Cholesteryl hemisuccinate incorporated lipid-based nano-carriers and skin-care compositions for external application containing the same
US20050191344A1 (en) * 2004-01-15 2005-09-01 Samuel Zalipsky Liposome composition for delivery of therapeutic agents
US8815599B2 (en) * 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
WO2006048329A1 (en) * 2004-11-05 2006-05-11 Novosom Ag Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent
JP2008520600A (ja) * 2004-11-19 2008-06-19 ノヴォソム アクチェンゲゼルシャフト 局所投与のための医薬組成物におけるまたはそれに関する改善
EP1764090A1 (en) * 2005-09-15 2007-03-21 Novosom AG Amphoteric liposomes for local drug applications
EP1911443A1 (en) * 2006-10-13 2008-04-16 Novosom AG Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
AU2006291429B2 (en) 2005-09-15 2013-04-04 Biontech Delivery Technologies Gmbh Improvements in or relating to amphoteric liposomes
PL1957044T3 (pl) * 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amfoteryczny preparat liposomowy
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
CA2665783C (en) 2006-10-13 2015-12-15 Novosom Ag Improvements in or relating to amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
HUE040417T2 (hu) 2007-05-04 2019-03-28 Marina Biotech Inc Aminosavlipidek és alkalmazásuk
US8822409B2 (en) 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
JP2009203228A (ja) * 2008-01-29 2009-09-10 Kochi Univ キレーター化合物含有薬物輸送剤
US8765171B2 (en) 2009-03-09 2014-07-01 The Regents Of The University Of California Methods and compositions for liposomal formulation of antigens and uses thereof
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
EP3318248B1 (en) * 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
CZ201181A3 (cs) * 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
WO2012159164A1 (en) 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
GB201116248D0 (en) * 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20150297725A1 (en) 2012-07-30 2015-10-22 Rutgers, The State University Of New Jersey Cochleates made with soy phosphatidylserine
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
EP4170031A1 (en) 2012-10-23 2023-04-26 Caris Science, Inc. Aptamers and uses thereof
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
AU2013361323B2 (en) 2012-12-19 2018-09-06 Caris Science, Inc. Compositions and methods for aptamer screening
US20170000715A1 (en) * 2014-01-29 2017-01-05 Humedix Co., Ltd. Pegylated 7-dehydrocholesterol derivatives
JP6399530B1 (ja) * 2017-09-04 2018-10-03 一丸ファルコス株式会社 ｐＨ感受性リポソーム
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
US12240824B2 (en) * 2018-05-30 2025-03-04 Translate Bio, Inc. Vitamin cationic lipids
EP3953473A1 (en) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
TW202305133A (zh) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna組合物及其使用方法
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2026027887A2 (en) 2024-08-02 2026-02-05 Mina Therapeutics Limited Hbg1/2-sarna compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891208A (en) 1985-04-10 1990-01-02 The Liposome Company, Inc. Steroidal liposomes
ATE45744T1 (de) 1984-07-25 1989-09-15 Ciba Geigy Ag Phosphatidylverbindungen, verfahren zu ihrer herstellung und ihre verwendung.
US4788162A (en) * 1985-12-23 1988-11-29 General Electric Company Composite by compression
US5993823A (en) * 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5365487A (en) * 1992-03-24 1994-11-15 Texas Instruments Incorporated DRAM power management with self-refresh
JP2579730B2 (ja) * 1993-01-22 1997-02-12 株式会社ディ・ディ・エス研究所 ペプチド−脂質誘導体及びリポソーム
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
DE59507224D1 (de) * 1994-12-28 1999-12-16 Max Delbrueck Centrum Neues cholesterolderivat für den liposomalen gentransfer
PT888379E (pt) 1996-03-01 2001-05-31 Centre Nat Rech Scient Compostos analogos a familia dos amidinios composicoes farmaceuticas que os contem e suas aplicacoes
WO1997039019A1 (en) 1996-04-12 1997-10-23 University Of Pittsburgh Novel cationic cholesteryl derivatives containing cyclic polar groups
DE69727384T2 (de) 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
DE19852928C1 (de) 1998-11-17 2000-08-03 Steffen Panzner Strukturen in Form von Hohlkugeln
US6342598B1 (en) * 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
GB2345868A (en) 1999-01-23 2000-07-26 Martin Hodgson Self adhesive magnetic or electromagnetic tapes
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
DE10010264A1 (de) * 2000-03-02 2001-09-13 Novosom Gmbh Stabilisierte Liposomen und Hüllstrukturen
GB0015624D0 (en) 2000-06-26 2000-08-16 Nat Cancer Centre Materials and methods relating to improved gene delivery

Also Published As

Publication number Publication date
DE50210313D1 (de) 2007-07-26
EP1806354A2 (de) 2007-07-11
EP1363932B1 (de) 2007-06-13
CA2438910A1 (en) 2002-08-29
JP4470197B2 (ja) 2010-06-02
WO2002066489A2 (de) 2002-08-29
AU2002302364B2 (en) 2008-01-03
WO2002066490A3 (de) 2003-04-24
BR0207776A (pt) 2004-03-23
US20040131666A1 (en) 2004-07-08
JP2004521917A (ja) 2004-07-22
EP1363932A2 (de) 2003-11-26
US7407947B2 (en) 2008-08-05
DE50213524D1 (de) 2009-06-18
EP1363933A2 (de) 2003-11-26
CN1492876A (zh) 2004-04-28
JP2004525902A (ja) 2004-08-26
CA2438910C (en) 2009-10-13
US7312206B2 (en) 2007-12-25
EP1363933B1 (de) 2009-05-06
AU2002244726A1 (en) 2002-09-04
ATE364620T1 (de) 2007-07-15
WO2002066490A2 (de) 2002-08-29
US20040120997A1 (en) 2004-06-24
DE10109898A1 (de) 2002-09-05
US20080113017A1 (en) 2008-05-15
CN1231493C (zh) 2005-12-14
WO2002066489A3 (de) 2003-01-03

Similar Documents

Publication Publication Date Title
ATE430759T1 (de) Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen
EE200000318A (et) Uudsed ühendid
ATE375999T1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
DE60223250D1 (de) Verfahren zur herstellung von alpha-hydroxysäure, glycolsäure und 2-hydroxyisobuttersäure aus dem entsprechenden alpha-hydroxynitril mittels nitrilase
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
DE60034728D1 (de) Verfahren zur Massenanfertigung von beschichteten, elektrochirurgischen Elektroden
DE69813523D1 (de) Polyalkoxysiloxanverbindungen,verfahren zur herstellung und diese verbindungen enthaltende beschichtungszusammensetzungen
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
DE69941954D1 (de) Oxetanderivate, oxetancopolymer, und verfahren zur herstellung von oxetanderivaten
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
ATE204851T1 (de) Verfahren zur herstellung von retrovial protease hemmenden zwischenprodukten
DE60239286D1 (de) Verfahren zur herstellung von trans-1,4-cyclohexandicarbonsäure
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE59804271D1 (de) Verfahren zur Herstellung von 4-Aminodiphenylamin
DE60002254T2 (de) Verfahren zur Herstellung von 4,6-diaminoresorcin
DE59900916D1 (de) Verfahren zur Herstellung von 4-Aminodiphenylamin
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
DE59803587D1 (de) Verfahren zur Herstellung von 4-Aminodiphenylamin
DE60214469D1 (de) Verfahren zur Herstellung von Zirkoniapulver
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE50205026D1 (de) Verfahren zur herstellung von n-substituierten 2,6-dialkylmorpholinen
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE339423T1 (de) Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
DE60004931D1 (de) Kontinuierliches Verfahren zur Herstellung von 3,5,5-Trimethylcyclohexa-3-en-1-on(beta-Isophoron)

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner